Press Releases

Recent Press Releases

07/14/2010

Plexxikon's Novel Agent Significantly Inhibits Activation of Key CNS Cells Associated With Alzheimer's Disease

06/06/2010

PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported

04/20/2010

Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, "First-in-Class" Cancer Drug

04/19/2010

Plexxikon Co-Founder Joseph Schlessinger, Ph.D., Awarded 2010 Pezcoller Foundation-AACR International Award for Cancer Research

01/08/2010

Plexxikon Announces First Patient Dosed in Phase 3 Trial

10/08/2009

Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial

09/30/2009

Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

09/23/2009

Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

09/10/2009

Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ECCO15 / ESMO34 2009 Conference

06/01/2009

Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients

05/15/2009

Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ASCO 2009 Annual Meeting

03/19/2009

Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

01/08/2009

Plexxikon and Roche Enter Second Partnership to Develop PLX5568 for Polycystic Kidney Disease

Archived Press Releases